Widely recognized as a global leader in strategic transactions, with bench strength in the U.S., Europe, and Asia, Covington advises on many of the industry's largest and most innovative life sciences transactions year after year. We leverage extensive cross-border experience and a deep understanding of industry-specific regulatory, IP, and commercial considerations to craft comprehensive, practical, and forward-looking solutions across the full range of strategic and commercial transactions.
Our Corporate Practice is consistently recognized for excellence by Chambers, Legal 500, and Corporate Board Member, and our Life Sciences Industry Group is ranked in the top tier for transactional, regulatory, IP, and litigation capabilities around the world by Chambers, Legal 500, Law 360 and LMG Life Sciences. Our life sciences transactional practice integrates these industry leading capabilities to meet the specialized needs of life sciences companies.
Collaborations, Licensing and Commercial Agreements
A hallmark of our transactional practice is our experience structuring, negotiating, and drafting strategic collaboration, licensing, co-development, co-promotion, technology transfer, and various types of commercial agreements, ranging from highly-complex global alliances to more standard licensing agreements.
We work collaboratively with our clients to develop pragmatic, flexible agreements that promote productive and lasting relationships by focusing on the shared business goals of all parties.
We have completed numerous cross-border and other corporate partnering deals for clients throughout the world. Our extensive work for established pharmaceutical and biotech companies gives us a deep understanding of later-stage and commercial agreements as well as complex research and discovery alliances. We have assisted with preparing standard agreement forms for co-promotion, contract sales force, distribution, and authorized generic deals, and are regularly called upon to provide benchmarking advice as well as to assist with restructuring and unwinding troubled or underperforming relationships negotiated by other firms.
Mergers and Acquisitions
Covington’s mergers and acquisitions team represents pharmaceutical, specialty pharmaceutical, biotech, and medical device companies in public and private acquisitions and dispositions globally. Overall, over the last few years, Covington’s mergers and acquisitions team has represented clients in and outside of the life science industry in over 500 completed transactions with an aggregate value in excess of $500 billion. We provide thorough and sophisticated analysis of the agreements, regulatory issues, and IP rights that are central to M&A transactions in the life sciences industry. Our M&A lawyers understand the sometimes fluid nature of transactions in the life sciences sector and have considerable experience working across disciplines on dual-track transactions and advising on deals as they evolve from acquisitions or dispositions to arrangements that are more collaborative in nature.
Life Sciences Finance and Royalty Monetizations
We represent a number of the leading life sciences lenders, along with biotech and healthcare companies looking to access capital in this market. Our life sciences finance experience encompasses financings for venture, growth oriented and established biotech and health care companies. We also have a leading practice in the highly specialized field of pharmaceutical royalty monetizations, a market we have been involved in since its inception more than 20 years ago. We regularly represent the principal participants in these transactions on both the buy and sell side, including financial investors, biotech and life sciences companies, individual inventors, and universities and non-profits.
Back
